Myriad Genetics Inc (NASDAQ:MYGN)

35.34
Delayed Data
As of Apr 17
 -0.155 / -0.44%
Today’s Change
31.56
Today|||52-Week Range
42.50
+3.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.5B

Company Description

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through three reportable segments: Research, Molecular Diagnostics and Companion Diagnostics. The Research segment focuses on the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The Molecular Diagnostics segment provides testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:

Employees

Shareholders

Other institutional69.09%
Mutual fund holders67.23%
Individual stakeholders2.39%

Top Executives

Peter D. MeldrumPresident, Chief Executive Officer & Director
Gary A. KingExecutive Vice President-International Operations
R. Bryan RiggsbeeChief Financial Officer, Treasurer & EVP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account